Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Enrolling by invitation Observational

Anthropometric Parameters of the Foot and Plantar Fasciitis

NCT07151066 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2024-12-15
Last updated
2025-09-03

Condition(s) studied

Plantar Fasciitis

Study summary

The aim of this study is to systematically evaluate anthropometric and lifestyle parameters in individuals diagnosed with PF and compare them with healthy individuals. This will reveal the structural and behavioural risk factors involved in the development of PF, providing a scientific basis for preventive measures and orthotic approaches.

Assessment Parameters:

Medical History Form

1. Demographic data: Age, height, weight, BMI
2. Foot anthropometric measurements
3. Footwear preference: Footwear Assessment Score ( Footwear Assessment Score )
4. Lower extremity joint health: History of pain, injury, or limitation in the knee and hip joints
5. Daily step count: Measurement using the Step Counter mobile application
6. Physical activity level: IPAQ-SF (International Physical Activity Questionnaire - Short Form) questionnaire

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Being between 18 and 65 years of age, * Having been diagnosed with plantar fasciitis, * Having heel pain complaints originating from the plantar medial calcaneal tubercle, * Pain complaints being most pronounced in the first steps taken in the morning or after rest, Exclusion Criteria: * Any cardiopulmonary, dermatological, neurological or orthopaedic problems, * History of lower limb surgery, * Use of assistive devices (walker, crutches, etc.) * Cognitive, mental and/or psychological problems * Pregnancy * Lower limb amputation

Primary outcome measure(s)

  • Anthropometric measurements of the foot — baseline
    * Foot length * Metatarsal width * Medial arch height

Trial sites (1)

FacilityCityRegionStatus
Istanbul Medipol University Istanbul Beykoz
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07151066 on ClinicalTrials.gov ↗ ← All trials in Turkey